Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (The PROCEED Study)
E
Evan Fogel, MD
Primary Investigator
Enrolling By Invitation
18-65 years
All
Phase
N/A
2 Locations
Brief description of study
This study will provide the most accurate and reliable estimates to date on disease progression and clinical events in evolving chronic pancreatitis. We also hope to develop from the results of this study some lab tests that will help us with early diagnosis of chronic pancreatitis and also to discover any genetic factors that may affect your chances of developing chronic pancreatitis. The results of this study may also provide information that will open opportunities for new drug discovery.
Detailed description of study
The purpose of this study is to estimate the risk of progression from suspected to definite CP, and the risk of new-onset diabetes or exocrine insufficiency in definite CP, and study how the risks are influenced by patient characteristics and conditions.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: chronic pancreatitis
-
Age: Between 18 Years - 65 Years
-
Gender: All
Inclusion Criteria
No personal history or symptoms of pancreatic disease
No upper abdominal symptoms
No family history of pancreatic disorders, celiac disease, cystic fibrosis
No history of acute infectious or inflammatory conditions requiring medical treatment or evaluation in the preceding 6 months
No history of cancer, except for non-melanoma skin cancers
No known pregnancy at the time of enrollment
No solid organ transplant or history of HIV/AIDS
Exclusion Criteria
History of bleeding disorders
Treatment with anticoagulants or antiplatelet therapy other than aspirin
Additional Information:No personal history or symptoms of pancreatic disease
No upper abdominal symptoms
No family history of pancreatic disorders, celiac disease, cystic fibrosis
No history of acute infectious or inflammatory conditions requiring medical treatment or evaluation in the preceding 6 months
No history of cancer, except for non-melanoma skin cancers
No known pregnancy at the time of enrollment
No solid organ transplant or history of HIV/AIDS
Exclusion Criteria
History of bleeding disorders
Treatment with anticoagulants or antiplatelet therapy other than aspirin
Participants will be compensated for their participation.
Updated on
01 Aug 2024.
Study ID: 1701080233, TX7713, GI-NIH-FOGEL-PROCEED, 10835
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
